Contract Pharma Manufacturing News

  1. Yatiri Bio Enters Exclusive Option To In-License Agreement With Oscotec For Denfivontinib In AML 3/24/2026

    Yatiri Bio, Inc., a leader in AI-driven precision medicine, today announced it has entered into an exclusive global option to license agreement with Oscotec, Inc. to develop and commercialize denfivontinib (SKI-G-801), a potent multikinase inhibitor, for the treatment of Acute Myeloid Leukemia (AML).

  2. SK pharmteco And Prozomix Announce Strategic Collaboration To Enhance Biocatalysis Capabilities For Global Drug Manufacturing 3/24/2026

     SK pharmteco, a leading global contract development and manufacturing organization (CDMO), and Prozomix, a pioneer in enzyme discovery and diversity, today announced a strategic partnership.

  3. Lentitek And ViroCell Announce Commercial Collaboration 3/23/2026

    As cell and gene therapies move toward increasingly complex genetic payloads, manufacturing challenges are emerging as a key bottleneck in the development of the next-generation of therapies.

  4. Bio-Thera Solutions Announces Further Expansion Of Partnership With Intas Pharmaceuticals For BAT2506, A Proposed Biosimilar Referencing Simponi® (golimumab), Through Exclusive Commercialization And License Agreement In India 3/23/2026

    Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced a further expansion of its partnership with Intas Pharmaceuticals for BAT2506, a proposed golimumab biosimilar, through an exclusive commercialization and license agreement for India.

  5. Cytiva And Yoshindo Advance Domestic Biosimilar Manufacturing In Japan Through FlexFactory Collaboration 3/23/2026

    Cytiva, a Danaher company and a leader in the life sciences industry, today announced that it has signed a FlexFactory contract with Yoshindo, supporting the company’s plans to establish domestic biosimilar drug substances manufacturing capabilities for the Japanese market.

  6. Lifecore Biomedical Signs Commercial Site Transfer Agreement With Leading Medical Aesthetics Company 3/23/2026

    Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product.

  7. Just – Evotec Biologics Enters Project Agreement With BARDA To Optimize Biomanufacturing Of Antibodies Against Ebola And Related Viruses 3/23/2026

    Evotec SE today announced its Seattle-based subsidiary and CDMO, Just – Evotec Biologics, Inc., has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufacturing optimization for a monoclonal antibody cocktail targeting filovirus diseases, including Ebola virus (EBOV) and Sudan virus (SUDV).

  8. Belief BioMed And Grand Life Sciences Announced Exclusive Commercial Partnership In The Field Of Hemophilia A, Bringing Innovative Gene Therapy To Chinese Patients 3/23/2026

    Belief BioMed ("BBM") and Grand Life Sciences Group Co., Ltd. ("Grand Life Sciences") today announced an exclusive collaboration agreement. Under the agreement, Belief BioMed will grant Grand Life Sciences the rights to commercialize its investigational product, BBM-H803, in Mainland China, Hong Kong China, Macau China, and Taiwan China.

  9. Eveliqure And Serum Institute Of India Announce Strategic Collaboration On The Development Of Anti-Diarrhoeal Vaccines 3/20/2026

    Eveliqure Biotechnologies GmbH, a clinical-stage biotechnology company focused on Shigella and ETEC vaccine development, and Serum Institute of India (SII), a Cyrus Poonawalla group company and the world's largest vaccine manufacturer, today announced a strategic collaboration and licence agreement for the development, manufacturing and commercialisation of novel anti-diarrhoeal vaccines targeting significant global health pathogens.

  10. Asimov Launches RNA Edge, A Lab-In-The-Loop Platform For AI Optimization Of RNA Therapeutic Candidates 3/19/2026

    Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, announces the launch of its RNA Edge System, an integrated AI, synthetic biology, and laboratory platform to optimize RNA therapies.